Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Eovist
Drug ID BADD_D00776
Description Gadoxetic acid (gadoxetate) is a paramagnetic gadolinium-containing contrast agent in which its salt form, gadoxetate disodium, is used for intravenous injection. Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up the drug. It is marketed by Bayer HealthCare Pharmaceuticals and FDA approved on July 3, 2008.
Indications and Usage Gadoxetate is used as a contrast medium for magnetic resonance imaging (MRI) to detect and characterize lesions in the liver.
Marketing Status Prescription
ATC Code V08CA10
DrugBank ID DB08884
KEGG ID D04288
MeSH ID C073590
PubChem ID 91754427
TTD Drug ID D0X2FT
NDC Product Code Not Available
Synonyms gadolinium ethoxybenzyl DTPA | Gd-EOB-DTPA | gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid | gadoxetic acid | gadoxetic acid disodium | gadoxetate disodium | disodium gadoxetate | gadolinium (4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanoic acid disodium salt | Eovist | Primovist
Chemical Information
Molecular Formula C23H28GdN3Na2O11
CAS Registry Number 135326-22-6
SMILES CCOC1=CC=C(C=C1)CC(CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O -].[Na+].[Na+].[Gd+3]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Injection site extravasation12.07.03.002; 08.02.03.002--Not Available
Injection site irritation12.07.03.027; 08.02.03.027--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Malaise08.01.01.003--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oral discomfort07.05.05.001--Not Available
Pallor24.03.04.001; 23.03.03.031; 08.01.03.032--Not Available
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
Parosmia22.04.03.007; 17.04.04.002--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Respiratory distress22.02.01.012--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Salivary hypersecretion07.06.01.009--Not Available
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Sneezing22.02.05.011--
Tachycardia02.03.02.007--Not Available
Tremor17.01.06.002--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.003--
Injection site coldness12.07.03.023; 08.02.03.023--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages